According to the brand, the multi-tasking spray should be applied both before and after makeup for a pore-blurring, natural ...

Wegovy's revenue jumped by 86% year over year to 58.2 billion DKK ($8.1 billion). It's no wonder Novo Nordisk's shares ... a mean weight loss of 22.7% in a 68-week phase 3 study; even though ...

Wegovy's revenue jumped by 86% year over year to 58.2 billion DKK ($8.1 billion). It's no wonder Novo Nordisk's shares jumped following the release of its fourth-quarter and full-year 2024 ...

Lilly has compared the effects of Zepbound and Wegovy in a head-to-head study, with Zepbound's 20.2% weight loss superior to Wegovy's 13.7%, so Novo is under some pressure to show it can compete ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Yeti has officially dropped its first seasonal color collections of 2025: Big Sky Blue and Firefly Yellow. The Big Sky Collection features a pastel, baby blue color while the Firefly Collection is ...

The company's shares were up 4.2% at 1527 GMT. The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

indicator is at a negative 2.60, signaling continued weakness, while the Relative Strength Index (RSI) sits at 41.89, hovering just above oversold territory. Investors should monitor whether Novo ...